Induced pluripotent stem cell (iPSC)-based therapies offer advantages in their potential to address clinical applicability and scalable manufacturing to meet patient demand. As the number of iPSC-based therapies in clinical development is increasing, the industry is seeing significant advancement following decades of development efforts. Despite these noteworthy strides, there are still many existing dilemmas to address for sustained progress and commercial viability.
In the pursuit of exploring the complexities within iPSC-based therapies, OmniaBio, a cell and gene therapy CDMO with deep iPSC expertise and capabilities, brings together a distinguished panel of industry experts. The panel aims to dissect the ever-evolving landscape of iPSC technology, highlighting crucial elements impacting efficient and effective clinical translation of these cell therapies. The panel aims to explore key areas such as material access and readiness, operational intricacies, technological innovations, and standardization. Join us as we delve into these critical aspects to reshape the future landscape of iPSC-based therapies.